세계의 중저소득 국가용 오피오이드 대체요법 시장 : 산업 분석, 시장 규모, 점유율, 성장 및 동향, 예측(2025-2032년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for opioid substitution therapy (OST) in Low and Middle Income Countries (LMICs). The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the OST market in LMICs from 2025 to 2032.

Key Insights:

• OST Market Size (2025E): USD 815.4 Mn
• Projected Market Value (2032F): USD 1,296.1 Mn
• Global Market Growth Rate (CAGR 2025 to 2032): 6.9%

Opioid Substitution Therapy Market - Report Scope:

Opioid substitution therapy (OST) plays a crucial role in the treatment of opioid dependence, particularly in Low and Middle Income Countries (LMICs). This therapy involves the use of medications such as methadone or buprenorphine to help individuals reduce or quit opioid use. The market for OST caters to various healthcare settings, including hospitals, addiction treatment centers, and rehabilitation facilities. Market growth is driven by increasing government awareness, policy changes supporting drug rehabilitation, and the rising burden of opioid use disorders in these regions. Additionally, expanding international funding and collaborations help increase accessibility and affordability of treatment options in LMICs.

Market Growth Drivers:

The global OST market in LMICs is propelled by several key factors, including a rising number of individuals affected by opioid use disorders and the increasing recognition of OST as an effective treatment for opioid dependence. Government initiatives and international support for harm reduction programs are fueling the market expansion. Enhanced access to OST in community-based treatment settings and the ongoing awareness campaigns regarding opioid addiction are essential drivers for market growth. Furthermore, the demand for affordable opioid replacement therapies in underserved regions supports market development. Technological advancements, such as the development of long-acting injectable buprenorphine and other medication-assisted treatment options, are contributing to improved patient outcomes and increased market adoption. These treatments are designed to address the specific needs of people in LMICs who may face barriers to daily clinic visits, providing more flexible treatment options and better adherence.

Market Restraints:

Despite promising growth prospects, the OST market in LMICs faces challenges related to limited healthcare budgets, regulatory hurdles, and stigma surrounding opioid dependence treatment. Economic constraints in many LMICs may hinder the affordability and availability of OST medications, particularly in rural or underserved areas. Additionally, insufficient healthcare infrastructure and trained personnel to administer and monitor OST present barriers to broader implementation. Social stigma related to addiction and substance use disorders also affects the willingness of individuals to seek OST, further restricting market growth.

Market Opportunities:

The OST market in LMICs presents significant growth opportunities driven by the continued expansion of government and non-governmental initiatives focusing on harm reduction. The introduction of cost-effective OST medications and expansion of treatment delivery models-such as mobile units and telemedicine-based monitoring-offer substantial growth potential. Furthermore, there is a rising opportunity to incorporate novel medications into OST programs, such as Sublocade, which could improve patient adherence and outcomes. As governments in LMICs begin to prioritize the treatment of opioid use disorder, there is ample opportunity for healthcare providers and pharmaceutical companies to develop tailored solutions to meet the unique needs of these regions. Partnerships between international organizations, governments, and NGOs can also drive growth and accessibility.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the OST market in LMICs?
• Which OST treatment options are most in demand in low-resource healthcare settings?
• How are technological advancements reshaping the competitive landscape of the OST market?
• Who are the key players contributing to the OST market in LMICs, and what strategies are they employing to enhance market reach?
• What are the emerging trends and future prospects in the OST market for Low and Middle Income Countries?

Competitive Intelligence and Business Strategy:

Leading players in the global OST market, including pharmaceutical companies like Indivior PLC, Camurus AB, and Methadone Research Corporation, focus on product differentiation, strategic partnerships, and innovation to maintain a competitive edge. These companies invest in R&D to develop more affordable and effective opioid dependence treatment solutions that cater specifically to the needs of populations in LMICs. Collaboration with governments and healthcare providers, along with the integration of community-based programs and telemedicine, enhances access to OST therapies and fosters long-term success.

Key Companies Profiled:

• Indivior PLC
• Camurus AB
• Methadone Research Corporation
• Sanofi
• Mylan N.V.
• Reckitt Benckiser Group PLC
• Opiant Pharmaceuticals, Inc.
• Alkermes PLC
• Mundipharma International Limited

Low and Middle Income Countries Opioid Substitution Therapy Market Research Segmentation

By Drug Class:

• Opioid Antagonists
• Naloxone
• Naltrexone
• Opioid Agonists and Partial Agonists
• Methadone
• Buprenorphine

By Indication:

• Pain Management
• Opioid Withdrawal/Opioid Use Disorder (OUD)
• Alcohol De-addiction
• Depression

By Distribution Channel:

• Government-supported Centers/NGO's/Tenders
• Institutional Sales
• Hospitals
• Psychiatric clinics
• Retail Pharmacies
• Online Sales

By Region:

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Low and Middle Income Countries Opioid Substitution Therapy Market Snapshot, 2025 - 2032
• 1.2. Market Opportunity Assessment, 2025 - 2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Drug Class Lifecycle Analysis
• 2.4. Low and Middle Income Countries Opioid Substitution Therapy Market: Value Chain
  • 2.4.1. List of Raw Material Supplier
  • 2.4.2. List of Manufacturers
  • 2.4.3. List of Distributors
  • 2.4.4. List of Applications
  • 2.4.5. Profitability Analysis
• 2.5. Porter Five Force's Analysis
• 2.6. Geopolitical Tensions: Market Impact
• 2.7. Macro-Economic Factors
  • 2.7.1. Global Sectorial Outlook
  • 2.7.2. Global GDP Growth Outlook
  • 2.7.3. Global Parent Market Overview
• 2.8. Forecast Factors - Relevance and Impact
• 2.9. Regulatory and Technology Landscape

3. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)

• 3.1. Key Highlights
  • 3.1.1. Market Volume (Units) Projections
  • 3.1.2. Market Size and Y-o-Y Growth
  • 3.1.3. Absolute $ Opportunity
• 3.2. Market Size (US$ Mn) Analysis and Forecast
  • 3.2.1. Historical Market Size Analysis, 2019 - 2023
  • 3.2.2. Current Market Size Forecast, 2025 - 2032
• 3.3. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook: Drug Class
  • 3.3.1. Introduction / Key Findings
  • 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Drug Class, 2019 - 2023
  • 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2025 - 2032
    • 3.3.3.1. Opioid Antagonists
    • 3.3.3.2. Naloxone
    • 3.3.3.3. Naltrexone
    • 3.3.3.4. Opioid Agonists and Partial Agonists
    • 3.3.3.5. Methadone
    • 3.3.3.6. Buprenorphine
• 3.4. Market Attractiveness Analysis: Drug Class
• 3.5. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook: Indication
  • 3.5.1. Introduction / Key Findings
  • 3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Indication, 2019 - 2023
  • 3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2025 - 2032
    • 3.5.3.1. Pain Management
    • 3.5.3.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
    • 3.5.3.3. Alcohol De-addiction
    • 3.5.3.4. Depression
• 3.6. Market Attractiveness Analysis: Indication
• 3.7. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook: Distribution Channel
  • 3.7.1. Introduction / Key Findings
  • 3.7.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Distribution Channel, 2019 - 2023
  • 3.7.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
    • 3.7.3.1. Government-supported Centers/NGO's/Tenders
    • 3.7.3.2. Institutional Sales
    • 3.7.3.3. Hospitals
    • 3.7.3.4. Psychiatric clinics
    • 3.7.3.5. Retail Pharmacies
    • 3.7.3.6. Online Sales
• 3.8. Market Attractiveness Analysis: Distribution Channel

4. Global Low and Middle Income Countries Opioid Substitution Therapy Market Outlook: Region

• 4.1. Key Highlights
• 4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2019 - 2023
• 4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2025 - 2032
  • 4.3.1. North America
  • 4.3.2. Europe
  • 4.3.3. East Asia
  • 4.3.4. South Asia & Pacific
  • 4.3.5. Latin America
  • 4.3.6. Middle East & Africa (MEA)
• 4.4. Market Attractiveness Analysis: Region

5. North America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)

• 5.1. Key Highlights
• 5.2. Pricing Analysis
• 5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2019 - 2023
  • 5.3.1. By Country
  • 5.3.2. By Drug Class
  • 5.3.3. By Indication
  • 5.3.4. By Distribution Channel
• 5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2025 - 2032
  • 5.4.1. U.S.
  • 5.4.2. Canada
• 5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2025 - 2032
  • 5.5.1. Opioid Antagonists
  • 5.5.2. Naloxone
  • 5.5.3. Naltrexone
  • 5.5.4. Opioid Agonists and Partial Agonists
  • 5.5.5. Methadone
  • 5.5.6. Buprenorphine
• 5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2025 - 2032
  • 5.6.1. Pain Management
  • 5.6.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
  • 5.6.3. Alcohol De-addiction
  • 5.6.4. Depression
• 5.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
  • 5.7.1. Government-supported Centers/NGO's/Tenders
  • 5.7.2. Institutional sales
  • 5.7.3. Hospitals
  • 5.7.4. Psychiatric clinics
  • 5.7.5. Retail Pharmacies
  • 5.7.6. Online Sales
• 5.8. Market Attractiveness Analysis

6. Europe Low and Middle Income Countries Opioid Substitution Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)

• 6.1. Key Highlights
• 6.2. Pricing Analysis
• 6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2019 - 2023
  • 6.3.1. By Country
  • 6.3.2. By Drug Class
  • 6.3.3. By Indication
  • 6.3.4. By Distribution Channel
• 6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2025 - 2032
  • 6.4.1. Germany
  • 6.4.2. France
  • 6.4.3. U.K.
  • 6.4.4. Italy
  • 6.4.5. Spain
  • 6.4.6. Russia
  • 6.4.7. Turkey
  • 6.4.8. Rest of Europe
• 6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2025 - 2032
  • 6.5.1. Opioid Antagonists
  • 6.5.2. Naloxone
  • 6.5.3. Naltrexone
  • 6.5.4. Opioid Agonists and Partial Agonists
  • 6.5.5. Methadone
  • 6.5.6. Buprenorphine
• 6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2025 - 2032
  • 6.6.1. Pain Management
  • 6.6.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
  • 6.6.3. Alcohol De-addiction
  • 6.6.4. Depression
• 6.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
  • 6.7.1. Government-supported Centers/NGO's/Tenders
  • 6.7.2. Institutional sales
  • 6.7.3. Hospitals
  • 6.7.4. Psychiatric clinics
  • 6.7.5. Retail Pharmacies
  • 6.7.6. Online Sales
• 6.8. Market Attractiveness Analysis

7. East Asia Low and Middle Income Countries Opioid Substitution Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)

• 7.1. Key Highlights
• 7.2. Pricing Analysis
• 7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2019 - 2023
  • 7.3.1. By Country
  • 7.3.2. By Drug Class
  • 7.3.3. By Indication
  • 7.3.4. By Distribution Channel
• 7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2025 - 2032
  • 7.4.1. China
  • 7.4.2. Japan
  • 7.4.3. South Korea
• 7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2025 - 2032
  • 7.5.1. Opioid Antagonists
  • 7.5.2. Naloxone
  • 7.5.3. Naltrexone
  • 7.5.4. Opioid Agonists and Partial Agonists
  • 7.5.5. Methadone
  • 7.5.6. Buprenorphine
• 7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2025 - 2032
  • 7.6.1. Pain Management
  • 7.6.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
  • 7.6.3. Alcohol De-addiction
  • 7.6.4. Depression
• 7.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
  • 7.7.1. Government-supported Centers/NGO's/Tenders
  • 7.7.2. Institutional sales
  • 7.7.3. Hospitals
  • 7.7.4. Psychiatric clinics
  • 7.7.5. Retail Pharmacies
  • 7.7.6. Online Sales
• 7.8. Market Attractiveness Analysis

8. South Asia & Oceania Low and Middle Income Countries Opioid Substitution Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)

• 8.1. Key Highlights
• 8.2. Pricing Analysis
• 8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2019 - 2023
  • 8.3.1. By Country
  • 8.3.2. By Drug Class
  • 8.3.3. By Indication
  • 8.3.4. By Distribution Channel
• 8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2025 - 2032
  • 8.4.1. India
  • 8.4.2. Southeast Asia
  • 8.4.3. ANZ
  • 8.4.4. Rest of South Asia & Oceania
• 8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2025 - 2032
  • 8.5.1. Opioid Antagonists
  • 8.5.2. Naloxone
  • 8.5.3. Naltrexone
  • 8.5.4. Opioid Agonists and Partial Agonists
  • 8.5.5. Methadone
  • 8.5.6. Buprenorphine
• 8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2025 - 2032
  • 8.6.1. Pain Management
  • 8.6.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
  • 8.6.3. Alcohol De-addiction
  • 8.6.4. Depression
• 8.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
  • 8.7.1. Government-supported Centers/NGO's/Tenders
  • 8.7.2. Institutional sales
  • 8.7.3. Hospitals
  • 8.7.4. Psychiatric clinics
  • 8.7.5. Retail Pharmacies
  • 8.7.6. Online Sales
• 8.8. Market Attractiveness Analysis

9. Latin America Low and Middle Income Countries Opioid Substitution Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)

• 9.1. Key Highlights
• 9.2. Pricing Analysis
• 9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2019 - 2023
  • 9.3.1. By Country
  • 9.3.2. By Drug Class
  • 9.3.3. By Indication
  • 9.3.4. By Distribution Channel
• 9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2025 - 2032
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America
• 9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2025 - 2032
  • 9.5.1. Opioid Antagonists
  • 9.5.2. Naloxone
  • 9.5.3. Naltrexone
• 9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2025 - 2032
  • 9.6.1. Pain Management
  • 9.6.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
  • 9.6.3. Alcohol De-addiction
  • 9.6.4. Depression
• 9.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
  • 9.7.1. Government-supported Centers/NGO's/Tenders
  • 9.7.2. Institutional sales
  • 9.7.3. Hospitals
  • 9.7.4. Psychiatric clinics
  • 9.7.5. Retail Pharmacies
  • 9.7.6. Online Sales
• 9.8. Market Attractiveness Analysis

10. Middle East & Africa Low and Middle Income Countries Opioid Substitution Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)

• 10.1. Key Highlights
• 10.2. Pricing Analysis
• 10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2019 - 2023
  • 10.3.1. By Country
  • 10.3.2. By Drug Class
  • 10.3.3. By Indication
  • 10.3.4. By Distribution Channel
• 10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2025 - 2032
  • 10.4.1. GCC
  • 10.4.2. Egypt
  • 10.4.3. South Africa
  • 10.4.4. Northern Africa
  • 10.4.5. Rest of Middle East & Africa
• 10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2025 - 2032
  • 10.5.1. Opioid Antagonists
  • 10.5.2. Naloxone
  • 10.5.3. Naltrexone
  • 10.5.4. Opioid Agonists and Partial Agonists
  • 10.5.5. Methadone
  • 10.5.6. Buprenorphine
• 10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2025 - 2032
  • 10.6.1. Pain Management
  • 10.6.2. Opioid Withdrawal/Opioid Use Disorder (OUD)
  • 10.6.3. Alcohol De-addiction
  • 10.6.4. Depression
• 10.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
  • 10.7.1. Government-supported Centers/NGO's/Tenders
  • 10.7.2. Institutional sales
  • 10.7.3. Hospitals
  • 10.7.4. Psychiatric clinics
  • 10.7.5. Retail Pharmacies
  • 10.7.6. Online Sales
• 10.8. Market Attractiveness Analysis

11. Competition Landscape

• 11.1. Market Share Analysis, 2024
• 11.2. Market Structure
  • 11.2.1. Competition Intensity Mapping By Market
  • 11.2.2. Competition Dashboard
  • 11.2.3. Apparent Product Capacity
• 11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 11.3.1. Indivior Inc.
    • 11.3.1.1. Overview
    • 11.3.1.2. Segments and Product
    • 11.3.1.3. Key Financials
    • 11.3.1.4. Market Developments
    • 11.3.1.5. Market Strategy
  • 11.3.2. Alkermes, Inc
    • 11.3.2.1. Overview
    • 11.3.2.2. Segments and Product
    • 11.3.2.3. Key Financials
    • 11.3.2.4. Market Developments
    • 11.3.2.5. Market Strategy
  • 11.3.3. Mundipharma GmbH
    • 11.3.3.1. Overview
    • 11.3.3.2. Segments and Product
    • 11.3.3.3. Key Financials
    • 11.3.3.4. Market Developments
    • 11.3.3.5. Market Strategy
  • 11.3.4. Viatris Inc
    • 11.3.4.1. Overview
    • 11.3.4.2. Segments and Product
    • 11.3.4.3. Key Financials
    • 11.3.4.4. Market Developments
    • 11.3.4.5. Market Strategy
  • 11.3.5. Intas Pharmaceuticals
    • 11.3.5.1. Overview
    • 11.3.5.2. Segments and Product
    • 11.3.5.3. Key Financials
    • 11.3.5.4. Market Developments
    • 11.3.5.5. Market Strategy
  • 11.3.6. Camurus
    • 11.3.6.1. Overview
    • 11.3.6.2. Segments and Product
    • 11.3.6.3. Key Financials
    • 11.3.6.4. Market Developments
    • 11.3.6.5. Market Strategy

12. Appendix

• 12.1. Research Methodology
• 12.2. Research Assumptions
• 12.3. Acronyms and Abbreviations